96 related articles for article (PubMed ID: 38456253)
1. Clinicopathological characteristics and tumor infiltrating immune cells associations of PD-L1 tumor expression in non-small cell lung cancer patients.
Aazzane O; Bakhtaoui FZ; Stitou S; Fellah H; Karkouri M
Tunis Med; 2024 Apr; 102(4):223-228. PubMed ID: 38746962
[TBL] [Abstract][Full Text] [Related]
2. Association of PD-L1 expression and clinical outcomes in ROS1 - rearranged advanced non-small cell lung cancer treated with crizotinib.
Zhang H; Zhang Z; Yan N; Li X
Front Oncol; 2024; 14():1405683. PubMed ID: 38835380
[TBL] [Abstract][Full Text] [Related]
3. Factors correlating the expression of PD-L1.
Lu F; Wang E; Liu H
BMC Cancer; 2024 May; 24(1):642. PubMed ID: 38796458
[TBL] [Abstract][Full Text] [Related]
4. PD-L1 expression in patients with non-small-cell lung cancer is associated with sex and genetic alterations: A retrospective study within the Caucasian population.
Sarova P; Mosleh B; Zehetmayer S; Oberndorfer F; Widder J; Prosch H; Aigner C; Idzko M; Hoda MA; Gompelmann D
Thorac Cancer; 2024 Jun; ():. PubMed ID: 38860475
[TBL] [Abstract][Full Text] [Related]
5. Multi-index comprehensive evaluation of the efficacy and response mechanism of immunotherapy in non-small cell lung cancer.
Fan J; Zhang T
Clin Transl Oncol; 2024 Jun; ():. PubMed ID: 38822977
[TBL] [Abstract][Full Text] [Related]
6. NKX2‑1 copy number alterations are associated with oncogenic, immunological and prognostic remodeling in non‑small cell lung cancer.
Luna HGC; Imasa MS; Juat N; Hernandez KV; Sayo TM; Cristal-Luna G; Asur-Galang SM; Bellengan M; Duga KJ; Buenaobra BB; De Los Santos MI; Medina D; Samo J; Literal VM; Sy-Naval S
Oncol Lett; 2024 Jul; 28(1):303. PubMed ID: 38774453
[TBL] [Abstract][Full Text] [Related]
7. Case report: Long-term intracranial effect of zimberelimab monotherapy following surgical resection of high PD-L1-expressing brain metastases from NSCLC.
Wu W; Guo J; He L; Deng Q; Huang X
Front Oncol; 2024; 14():1390343. PubMed ID: 38800395
[TBL] [Abstract][Full Text] [Related]
8. Comprehensive Characterization of Cancer Driver Genes and Mutations.
Bailey MH; Tokheim C; Porta-Pardo E; Sengupta S; Bertrand D; Weerasinghe A; Colaprico A; Wendl MC; Kim J; Reardon B; Ng PK; Jeong KJ; Cao S; Wang Z; Gao J; Gao Q; Wang F; Liu EM; Mularoni L; Rubio-Perez C; Nagarajan N; Cortés-Ciriano I; Zhou DC; Liang WW; Hess JM; Yellapantula VD; Tamborero D; Gonzalez-Perez A; Suphavilai C; Ko JY; Khurana E; Park PJ; Van Allen EM; Liang H; ; ; Lawrence MS; Godzik A; Lopez-Bigas N; Stuart J; Wheeler D; Getz G; Chen K; Lazar AJ; Mills GB; Karchin R; Ding L
Cell; 2018 Apr; 173(2):371-385.e18. PubMed ID: 29625053
[TBL] [Abstract][Full Text] [Related]
9. An analysis of the influencing factors of false negative autoantibodies in patients with non-small cell lung cancer.
Wang A; Hao Y; Huo Y; Xu X; Zhang Y
Front Oncol; 2024; 14():1358387. PubMed ID: 38800369
[TBL] [Abstract][Full Text] [Related]
10. PD-L1 expression in advanced NSCLC: Insights into risk stratification and treatment selection from a systematic literature review.
Brody R; Zhang Y; Ballas M; Siddiqui MK; Gupta P; Barker C; Midha A; Walker J
Lung Cancer; 2017 Oct; 112():200-215. PubMed ID: 29191596
[TBL] [Abstract][Full Text] [Related]
11. Predictive markers in lung cancer: a few hints for the practicing pathologist.
Barbareschi M; Barberis M; Buttitta F; Doglioni C; Fiorentino M; Fontanini G; Franco R; Marchetti A; Rossi G; Troncone G
Pathologica; 2018 Mar; 110(1):29-38. PubMed ID: 30259911
[TBL] [Abstract][Full Text] [Related]
12. Association of PD-L1 expression with driver gene mutations and clinicopathological characteristics in non-small cell lung cancer: A real-world study of 10 441 patients.
Ruiz G; Enrico D; Mahmoud YD; Ruiz A; Cantarella MF; Leguina L; Barberis M; Beña A; Brest E; Starapoli S; Mendoza Bertelli A; Tsou F; Pupareli C; Coppola MP; Scocimarro A; Sena S; Levit P; Perfetti A; Aman E; Girotti MR; Arrieta O; Martín C; Salanova R
Thorac Cancer; 2024 Apr; 15(11):895-905. PubMed ID: 38456253
[TBL] [Abstract][Full Text] [Related]
13. The prognostic role of PD-1, PD-L1, ALK, and ROS1 proteins expression in non-small cell lung carcinoma patients from Egypt.
Bahnassy AA; Ismail H; Mohanad M; El-Bastawisy A; Yousef HF
J Egypt Natl Canc Inst; 2022 May; 34(1):23. PubMed ID: 35644823
[TBL] [Abstract][Full Text] [Related]
14. Correlation between Programmed Death Ligand-1(PD-L1) Expression and Driver Gene Mutations in Non-Small Cell Lung Carcinoma- Adenocarcinoma Phenotype.
Pandey RK; Shukla S; Husain N; Islam MH; Hadi R; Kant Tripathi S; Singhal A
Asian Pac J Cancer Prev; 2022 Jan; 23(1):131-142. PubMed ID: 35092381
[TBL] [Abstract][Full Text] [Related]
15. Common driver mutations and programmed death-ligand 1 expression in advanced non-small cell lung cancer in smokers and never smokers.
Liam CK; Yew CY; Pang YK; Wong CK; Poh ME; Tan JL; Soo CI; Loh TC; Chin KK; Munusamy V; Liam YS; Ibrahim NH
BMC Cancer; 2023 Jul; 23(1):659. PubMed ID: 37452277
[TBL] [Abstract][Full Text] [Related]
16.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
17.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
18.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
